medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 3

<< Back Next >>

Ann Hepatol 2018; 17 (3)

Antiproliferative Effects of Epigenetic Modifier Drugs through E-cadherin Up-regulation in Liver Cancer Cell Lines

Uribe D, Cardona A, Degli ED, Cros Marie-Pierre; Cuenin C, Herceg Z, Camargo M, Cortés-Mancera FM

Language: English
References: 48
Page: 444-460
PDF size: 894.73 Kb.


ABSTRACT

Introduction and aim. Epigenetic alterations play an essential role in cancer onset and progression, thus studies of drugs targeting the epigenetic machinery are a principal concern for cancer treatment. Here, we evaluated the potential of the DNA methyltransferase inhibitor 5-aza-2’-deoxycytidine (5aza-dC) and the pan-deacetylase inhibitor Trichostatin A (TSA), at low cytotoxic concentrations, to modulate the canonical Wnt/β-catenin pathway in liver cancer cells. Material and methods. Pyrosequencing was used for DNA methylation analyses of LINE-1 sequences and the Wnt/β-catenin pathway antagonist DKK3, SFRP1, WIF1 and CDH1. qRT-PCR was employed to verify the expression of the antagonist. Pathway regulation were evaluated looking at the expression of β-catenin and E-cadherin by confocal microscopy and the antitumoral effects of the drugs was studied by wound healing and clonogenic assays. Results. Our result suggest that 5aza-dC and TSA treatments were enough to induce a significant expression of the pathway antagonists, decrease of β-catenin protein levels, re-localization of the protein to the plasma membrane, and pathway transcriptional activity reduction. These important effects exerted an antitumoral outcome shown by the reduction of the migration and clonogenic capabilities of the cells. Conclusion. We were able to demonstrate Wnt/ β-catenin pathway modulation through E-cadherin up-regulation induced by 5aza-dC and TSA treatments, under an activation-pathway background, like CTNNB1 and TP53 mutations. These findings provide evidences of the potential effect of epigenetic modifier drugs for liver cancer treatment. However, further research needs to be conducted, to determine the in vivo potential of this treatment regimen for the management of liver cancer.


REFERENCES

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr [accessed on 11/06/2015].

  2. Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol 2013; 59: 1107-17.

  3. Valenta T, Hausmann G, Basler K. The many faces and functions of b-catenin. EMBO J 2012; 31: 2714-36.

  4. van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009; 136: 3205-14.

  5. MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: Components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.

  6. Brembeck FH, Rosário M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006; 16: 51-9.

  7. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-12.

  8. Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta 2013; 424: 53-65.

  9. Taniguchi H, Yamamoto H, Hirata Y, Miyamoto N, Oki M, Nosho K, Adachi Y, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005; 24: 7946-52.

  10. Kaur P, Mani S, Cros MP, Scoazec JY, Chemin I, Hainaut P, Herceg Z. Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. Tumour Biol 2012; 33: 325-36.

  11. Dhanak D, Jackson P. Development and classes of epigenetic drugs for cancer. Biochem Biophys Res Commun 2014; 455: 58-69.

  12. Wongtrakoongate P. Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries. World J Stem Cells 2015; 7: 137-48.

  13. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30-9.

  14. Cagatay T, Ozturk M. P53 mutation as a source of aberrant beta-catenin accumulation in cancer cells. Oncogene 2002; 21: 7971-80.

  15. Chai G, Li L, Zhou W, Wu L, Zhao Y, Wang D, Lu S, et al. HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS One 2008; 3: e2445.

  16. Jung N, Won JK, Kim BH, Suh KS, Jang JJ, Kang GH. Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma. J Korean Med Sci 2012; 27: 594-604.

  17. Nishida N, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, et al. Identification of epigenetically inactivated genes in human hepatocellular carcinoma by integrative analyses of methylation profiling and pharmacological unmasking. Dig Dis 2014; 32: 740-6.

  18. Mossman D, Kim KT, Scott RJ. Demethylation by 5-aza-2'- deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. BMC Cancer 2010; 10: 366.

  19. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.

  20. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G, McKay-Chopin S, Tavtigian SV, Scoazec JY, et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 2010; 5: e9749.

  21. Guzmán C, Bagga M, Kaur A, Westermarck J, Abankwa D. Colony Area: an Image J plugin to automatically quantify colony formation in clonogenic assays. PLoS One 2014; 9: e92444.

  22. Cardona A, Ariza-Jiménez L, Uribe D, Arroyave JC, Galeano J, Cortés-Mancera FM. Bio-EdIP: An automatic approach for in vitro cell confluence images quantification. Comput Methods Programs Biomed 2017; 145: 23-33.

  23. Suarez IM, Uribe D, Jaramillo CM, Osorio G, Perez JC, Lopez R, Hoyos S, et al. Wnt/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia. Ann Hepatol 2015; 14: 64-74.

  24. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012; 22: 9-20.

  25. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 2013; 13: 497-510.

  26. Cecconi D, Donadelli M, Dalla Pozza E, Rinalducci S, Zolla L, Scupoli MT, Righetti PG, et al. Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. Proteomics 2009; 9: 1952-66.

  27. Zuo X, Qin Y, Zhang X, Ning Q, Shao S, Luo M, Yuan M, et al. Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI. Oncol Rep 2014; 31: 2358-64.

  28. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012; 21: 430-46.

  29. Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One 2011; 6: e17388.

  30. Götze S, Wolter M, Reifenberger G, Müller O, Sievers S. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer 2010; 126: 2584-93.

  31. Kawamoto K, Hirata H, Kikuno N, Tanaka Y, Nakagawa M, Dahiya R. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int J Cancer 2008; 123: 535-42.

  32. Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knüchel R, Dahl E. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast Cancer Res 2008; 10: R82.

  33. Chowdhury B, McGovern A, Cui Y, Choudhury SR, Cho IH, Cooper B, Chevassut T, et al. The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells. Sci Rep 2015; 5: 9281.

  34. Sirchia SM, Faversani A, Rovina D, Russo MV, Paganini L, Savi F, Augello C, et al. Epigenetic effects of chromatin remodeling agents on organotypic cultures. Epigenomics 2016; 8: 341-58.

  35. Ivanov M, Kals M, Lauschke V, Barragan I, Ewels P, Käller M, Axelsson T, et al. Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression. Nucleic Acids Res 2016; 44: 6756-69.

  36. Peinado H, Ballestar E, Esteller M, Cano A. Snail mediates Ecadherin repression by the recruitment of the Sin3A/histone deacetylase 1(HDAC1)/HDAC2 complex. Mol Cell Biol 2004; 24: 306-19.

  37. Arzumanyan A, Friedman T, Kotei E, Ng IO, Lian Z, Feitelson MA. Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer. Oncogene 2012; 31: 563-72.

  38. Chen YJ, Luo J, Yang GY, Yang K, Wen SQ, Zou SQ. Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma. World J Gastroenterol 2012; 18: 3849-61.

  39. Shang D, Liu Y, Xu X, Han T, Tian Y. 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression. Cancer Lett 2011; 311: 230-36.

  40. Kim JT, Li J, Jang ER, Gulhati P, Rychahou PG, Napier DL, Wang C, et al. Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. Carcinogenesis 2013; 34: 953- 61.

  41. Shin H, Kim JH, Lee YS, Lee YC. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling. Int J Oncol 2012; 40: 1533-42.

  42. Hu J, Dong A, Fernandez-Ruiz V, Shan J, Kawa M, Martínez- Ansó E, Prieto J, et al. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res 2009; 69: 6951-9.

  43. Catalano MG, Fortunati N, Pugliese M, Marano F, Ortoleva L, Poli R, Asioli S, et al. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2012; 97: E1150-9.

  44. Huels DJ, Ridgway RA, Radulescu S, Leushacke M, Campbell AD, Biswas S, et al. E-cadherin can limit the transforming properties of activating β-catenin mutations. EMBO J 2015; 34: 2321-33.

  45. Kuphal F, Behrens J. E-cadherin modulates Wnt-dependent transcription in colorectal cancer cells but does not alter Wnt-independent gene expression in fibroblasts. Exp Cell Res 2006; 312: 457-67.

  46. Shih YL, Hsieh CB, Lai HC, Yan MD, Hsieh TY, Chao YC, Lin YW. SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int J Cancer 2007; 121: 1028-35.

  47. Ding SL, Yang ZW, Wang J, Zhang XL, Chen XM, Lu FM. Integrative analysis of aberrant Wnt signaling in hepatitis B virus- related hepatocellular carcinoma. World J Gastroenterol 2015; 21: 6317-28.

  48. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36: 417-22.




2020     |     www.medigraphic.com